# Treatment Development of Triheptanoin (G1D)

> **NCT03041363** · PHASE1 · COMPLETED · sponsor: **Juan Pascual** · enrollment: 12 (actual)

## Conditions studied

- Epilepsy
- GLUT1DS1
- Glut1 Deficiency Syndrome 1, Autosomal Recessive
- Glucose Metabolism Disorders
- Glucose Transport Defect
- Glucose Transporter Type 1 Deficiency Syndrome
- Glucose Transporter Protein Type 1 Deficiency Syndrome

## Interventions

- **DRUG:** Triheptanoin

## Key facts

- **NCT ID:** NCT03041363
- **Lead sponsor:** Juan Pascual
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-29
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041363, "Treatment Development of Triheptanoin (G1D)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03041363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*